More support for the judicious use of high-dose interleukin-2 in patients with advanced melanoma.
McDermott
David F
DF
Atkins
Michael B
MB
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000139:chemically induced; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary*; D018579:Patient Selection; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology
D007376:Interleukin-2